These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 16489684)

  • 1. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
    Ji GZ; Wang XH; Miao L; Liu Z; Zhang P; Zhang FM; Yang JB
    World J Gastroenterol; 2006 Jan; 12(4):644-8. PubMed ID: 16489684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells.
    Grau AM; Datta PK; Zi J; Halder SK; Beauchamp RD
    Cell Signal; 2006 Jul; 18(7):1041-50. PubMed ID: 16288847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta.
    Park YN; Chae KJ; Oh BK; Choi J; Choi KS; Park C
    Hepatogastroenterology; 2004; 51(56):396-400. PubMed ID: 15086168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma.
    Abou-Shady M; Baer HU; Friess H; Berberat P; Zimmermann A; Graber H; Gold LI; Korc M; Büchler MW
    Am J Surg; 1999 Mar; 177(3):209-15. PubMed ID: 10219856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of the expression of Smad4, transforming growth factor beta(1) and beta receptor II proteins in paraffin-embedded human pancreatic cancer tissues].
    Gu L; Chen J; Liu T; Li L; Lu Z; Luo Y
    Zhonghua Bing Li Xue Za Zhi; 2001 Dec; 30(6):439-42. PubMed ID: 11866987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.
    Torbenson M; Marinopoulos S; Dang DT; Choti M; Ashfaq R; Maitra A; Boitnott J; Wilentz RE
    Hum Pathol; 2002 Sep; 33(9):871-6. PubMed ID: 12378510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of transforming growth factor-beta signaling pathway in pathogenesis of benign biliary stricture.
    Geng ZM; Zheng JB; Zhang XX; Tao J; Wang L
    World J Gastroenterol; 2008 Aug; 14(31):4949-54. PubMed ID: 18756605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis.
    Lu Y; Wu LQ; Li CS; Wang SG; Han B
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):174-8. PubMed ID: 18397854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.
    Arsura M; Panta GR; Bilyeu JD; Cavin LG; Sovak MA; Oliver AA; Factor V; Heuchel R; Mercurio F; Thorgeirsson SS; Sonenshein GE
    Oncogene; 2003 Jan; 22(3):412-25. PubMed ID: 12545162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
    Lange D; Persson U; Wollina U; ten Dijke P; Castelli E; Heldin CH; Funa K
    Int J Oncol; 1999 Jun; 14(6):1049-56. PubMed ID: 10339656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-β and NF-κB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers.
    Freudlsperger C; Bian Y; Contag Wise S; Burnett J; Coupar J; Yang X; Chen Z; Van Waes C
    Oncogene; 2013 Mar; 32(12):1549-59. PubMed ID: 22641218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells.
    Heldin NE; Bergström D; Hermansson A; Bergenstråhle A; Nakao A; Westermark B; ten Dijke P
    Mol Cell Endocrinol; 1999 Jul; 153(1-2):79-90. PubMed ID: 10459856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlations of TGF-betaRII, Smad4 and Smad7 expression to clinicopathologic characteristics and prognosis of gastric cancer].
    Lu B; Zhou YN; Li Q; Wu ZQ; Zhang ZY; Ji R; Guo QH; Liu W
    Ai Zheng; 2009 May; 28(5):538-42. PubMed ID: 19624886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Chinese traditional compound, JinSanE, on expression of TGF-beta1 and TGF-beta1 type II receptor mRNA, Smad3 and Smad7 on experimental hepatic fibrosis in vivo.
    Song SL; Gong ZJ; Zhang QR; Huang TX
    World J Gastroenterol; 2005 Apr; 11(15):2269-76. PubMed ID: 15818738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer.
    Gulubova M; Manolova I; Ananiev J; Julianov A; Yovchev Y; Peeva K
    Int J Colorectal Dis; 2010 May; 25(5):591-9. PubMed ID: 20165854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-β signaling pathway in Marfan's syndrome: a preliminary histopathological study.
    Yuan SM; Ma HH; Zhang RS; Jing H
    Vasa; 2011 Sep; 40(5):369-74. PubMed ID: 21948779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells.
    Mu X; Lin S; Yang J; Chen C; Chen Y; Herzig MC; Washburn K; Halff GA; Walter CA; Sun B; Sun LZ
    PLoS One; 2013; 8(5):e63436. PubMed ID: 23704908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor.
    Persson U; Souchelnytskyi S; Franzén P; Miyazono K; ten Dijke P; Heldin CH
    J Biol Chem; 1997 Aug; 272(34):21187-94. PubMed ID: 9261125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin plus norcantharidin alter the expression of TGF-β1/Smads signaling pathway in hepatocellular carcinoma.
    Li KY; Shi CX; Huang JZ; Tang KL
    Bratisl Lek Listy; 2017; 118(2):85-88. PubMed ID: 28814088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.